- Impact of sustained disability progression and relapses on visual outcomes in the AFFIRM trialPublikace bez příslušnosti k fakultě
- Confirmed disability progression as a marker of permanent disability in multiple sclerosis2022 | 1. lékařská fakulta
- Měření atrofie corpus callosum a porovnání s ostatními metodami monitorace roztroušené sklerózy2012 | 1. lékařská fakulta
- Combining clinical and magnetic resonance imaging markers enhances prediction of 12-year disability in multiple sclerosis2017 | 1. lékařská fakulta
- Effect of daclizumab high-yield process in patients with highly active relapsing-remitting multiple sclerosis2014 | 1. lékařská fakulta
- MRI correlates of disability progression in patients with CIS over 48 months2014 | 1. lékařská fakulta, Fakulta tělesné výchovy a sportu
- Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis2015 | 1. lékařská fakulta
- Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS2017 | 1. lékařská fakulta
- The incidence and significance of anti-natalizumab antibodies - Results from AFFIRM and SENTINEL2007 | 2. lékařská fakulta
- Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis2009 | Publikace bez příslušnosti k fakultě
- Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension2018 | 1. lékařská fakulta